The identification of oncogenic activation of tyrosine kinases in NSCLC, such as mutations in epidermal growth factor receptor (EGFR) or rearrangements of the anaplastic lymphoma kinase (ALK) gene, has enabled targeted molecular treatments which along with immunotherapy has brought about a paradigm change in the treatment landscape. This evidence concerns the gene ALK and non-small cell lung carcinoma.